Oral drug for rifampicin-resistant lung tuberculosis
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This Phase 3 trial tests an oral medicine (Sudapyridine/WX-081) to treat people with rifampicin-resistant pulmonary tuberculosis. It compares how well the study drug works when you stop prior tuberculosis medicines and go through a short “washout” period first.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Have lung tuberculosis that is confirmed to be resistant to rifampicin (from a test done within the last 3 months)
- Have a positive sputum test showing tuberculosis bacteria (acid-fast bacilli at least 1+)
- Be able to stop all previous tuberculosis medicines and wait 7 days before starting the study drug
- Be within the study body size limits (BMI 15.0 to 28.0, and weight 40 to 90 kg)
- Not be pregnant or breastfeeding; if you are, you must agree to contraception during the study (or for men, your spouse must use contraception)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of drugs for people with active tuberculosis who have not been treated before. It aims to find a better way to treat TB, even if the bacteria are resistant to some drugs.
This trial tests a shorter treatment for tuberculosis (TB) using a combination of three medicines: bedaquiline, moxifloxacin, and pyrazinamide. If you have TB in your lungs, this could be a way to treat it more quickly than the standard longer course.
This trial tests how a new drug, sudapyridine, interacts with two common medicines (itraconazole and rifampin) and whether food changes how the drug is absorbed. It is for healthy adults to help find the right dosing and safety for future patients.
This trial tests a personalized treatment approach for people with rifampicin-resistant TB that is still sensitive to fluoroquinolones. It aims to find the best combination of medicines based on your specific TB profile.
This study tests a 6-month treatment with four oral medicines (bedaquiline, delamanid, linezolid, and levofloxacin) for people whose TB is resistant to rifampin. The goal is to see if this all-pill combination is safe and effective in treating this difficult type of TB.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
Hear when a new Rifampin-Resistant Pulmonary Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.